Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib
The Indian government's move to issue compulsory licences to three more patented cancer drugs has left a few of the pharma multinational in a lurch, reports the local Business Standard newspaper.
The government, according to the newspaper, plans to issue compulsory licences for cancer drugs such as Roche’s (ROG: SIX) Herceptin (trastuzumab), used for breast cancer, and Bristol-Myers Squibb’s (NYSE: BMY) Ixempra (ixabepilone) for breast cancer treatment and Sprycel (dasatinib), for leukemia. It would be the first round of new compulsory licenses since India issued its first last March, on Bayer's kidney cancer treatment Nexavar (sorafenib; The Pharma letters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze